

Takeda Pharmaceutical Company Limited (4502:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends

Company Report | 2025-02-27 | 142 pages | Quaintel Research

AVAILABLE LICENSES:

- Single User Price \$175.00
- Multi User Price \$195.00
- Enterprise User Price \$225.00

Report description:

Report Summary

Takeda Pharmaceutical Company Limited (4502:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Takeda Pharmaceutical Company Limited's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.

The report begins with in-depth information about Takeda Pharmaceutical Company Limited, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.

Next, the report assesses Takeda Pharmaceutical Company Limited's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Takeda

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pharmaceutical Company Limited's overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Takeda Pharmaceutical Company Limited's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Takeda Pharmaceutical Company Limited's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.

Finally, the report includes recent news and deal activities undertaken by Takeda Pharmaceutical Company Limited, enhancing awareness of the company's business trends, growth perspectives, and more.

Key Highlights

Takeda Pharmaceutical Company Limited operates as a global biopharmaceutical company that engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. Takeda operates in the pharmaceutical industry through two main business segments - prescription drugs and consumer healthcare products. The prescription drugs segment covers gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience.

The consumer healthcare segment includes over-the-counter medicines. Takeda offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. Some of its key products include Entyvio for ulcerative colitis and Crohn's disease, Gattex for short bowel syndrome, Takecab for gastroesophageal reflux disease, Alofisel for complex perianal fistulas, and Dexilant for acid reflux disease. It also offers factor replacement therapies, monoclonal antibodies, targeted cancer therapies, and treatments for central nervous system disorders. Founded in 1781, the company is headquartered in Tokyo, Japan.

Takeda Pharmaceutical Company Limited in the News:-

- 24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
- 24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
- 16-Jan-2025 - Takeda Named Global Top Employer for Eighth Consecutive Year
- 27-Dec-2024 - Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
- 13-Dec-2024 - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Scope

- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

- Comprehensive Understanding of the Takeda Pharmaceutical Company Limited's internal and external factors through SWOT analysis, PESTLE analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Takeda Pharmaceutical Company Limited:

- Takeda Pharmaceutical Company Limited Porter's Five Forces Analysis
- Takeda Pharmaceutical Company Limited VRIO Analysis
- Takeda Pharmaceutical Company Limited BCG Analysis
- Takeda Pharmaceutical Company Limited Segmentation, Targeting and Positioning (STP) Analysis
- Takeda Pharmaceutical Company Limited Ansoff Matrix Analysis

Table of Contents:

Table of Contents	
COMPANY EXECUTIVE SUMMARY	1
Table of Contents	2
Tables	7
Charts	8
Takeda Pharmaceutical Company Limited - Key Company Facts	9
Takeda Pharmaceutical Company Limited - Company Description	10
Takeda Pharmaceutical Company Limited - Top Executives	11
Takeda Pharmaceutical Company Limited- Head Office & Locations	13
Head Office - Country	13
Takeda Pharmaceutical Company Limited - Products and Services	14
Products	14
Services	16
Takeda Pharmaceutical Company Limited - Company's Mission and Vision	18
Mission	18
Vision	18
Takeda Pharmaceutical Company Limited - Corporate Strategy	19

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Takeda Pharmaceutical Company Limited - Business Description	27
Oncology	28
Rare Diseases	28
PDT immunology	29
Gastroenterology (GI)	29
Others	30
Takeda Pharmaceutical Company Limited - ESG Spotlight	31
Environment	31
Social	32
Corporate Governance	33
Takeda Pharmaceutical Company Limited - SWOT Analysis	34
Overview	34
Strengths	36
Weaknesses	39
Opportunities	41
Threats	43
Takeda Pharmaceutical Company Limited - PESTLE Analysis	45
Overview	45
Political Factors	47
Economic Factors	50
Social Factors	52
Technological Factors	54
Legal Factors	55
Environmental Factors	57
Takeda Pharmaceutical Company Limited - Financial Deep Dive	60
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price)	60
Profit and Loss Statement	62
Summary of Profit and Loss Statement	62
Balance Sheet	64
Summary of Balance Sheet	64
Cash Flow Statement	66
Summary of Cash Flow Statement	66
Key Financial Ratio Analysis	68
Takeda Pharmaceutical Company Limited - Ratio Charts	69
Activity Ratio Charts	69
Growth Ratios Charts	70
Leverage Ratio Charts	71
Liquidity Ratio Charts	72
Profitability Ratio Charts	73
Competing Players	74
Snapshot of Competing Players	75
AbbVie Inc	75
Key Company Facts	75
Company Description	75
Novartis AG	76
Key Company Facts	76
Company Description	76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pfizer Inc.	77
Key Company Facts	77
Company Description	77
Merck & Co., Inc.	78
Key Company Facts	78
Company Description	78
F. Hoffmann-La Roche Ltd	79
Key Company Facts	79
Company Description	79
Takeda Pharmaceutical Company Limited - In the News	80
24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (Ivanadumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)	80
24-Feb-2025 - The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO (Ivanadumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)	81
16-Jan-2025 - Takeda Named Global Top Employer for Eighth Consecutive Year	81
27-Dec-2024 - Takeda Announces Approval of HYQVIA 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia	83
13-Dec-2024 - Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas	85
24-Sep-2024 - Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer	87
18-Sep-2024 - Takeda Commits Over \$32 Million in Five New Global Corporate Social Responsibility Partnerships To Further Drive Health Impact in 93 Countries	87
07-Aug-2024 - Takeda Receives European Commission Approval for ADZYNMA (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	91
09-May-2024 - Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	93
26-Apr-2024 - Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	93
18-Apr-2024 - U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	95
15-Apr-2024 - Notice Regarding Issuance of JPY Hybrid Bonds	96
26-Mar-2024 - Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting	97
26-Mar-2024 - Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	97
19-Mar-2024 - Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL	99
12-Feb-2024 - FDA Approves Takeda's EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)	101
29-Jan-2024 - Takeda's GAMMAGARD LIQUID Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	105
16-Jan-2024 - U.S. FDA Approves Takeda's HYQVIA as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	108
21-Dec-2023 - Takeda Announces China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies	111
Takeda Pharmaceutical Company Limited - Key Deals	112
30-Jan-2025 - Takeda Announces Acquisition of Own Shares	112
30-Jan-2025 - Takeda Announces Acquisition of Own Shares	113

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

03-Dec-2024 - Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics	113
14-Jun-2024 - Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	115
13-May-2024 - AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease	117
26-Feb-2024 - Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas	119
31-Jan-2024 - Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	120
13-Sep-2023 - Takeda Commits Over \$30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 Countries	122
23-Mar-2023 - Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan	125
08-Feb-2023 - Takeda Completes Acquisition of Nimbus Therapeutics' TYK2 Program Subsidiary	127
23-Jan-2023 - Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor	127
13-Dec-2022 - Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics	130
20-Oct-2022 - Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy	132
19-Sep-2022 - Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States	134
Appendix	136
Definitions	136
SWOT Analysis	136
PESTLE Analysis	136
Value Chain Analysis	136
ESG Spotlight	136
Financial Deep Dive	136
Financial Ratios -	137
Activity Ratios	137
Growth Ratios	138
Leverage Ratios	139
Liquidity Ratios	140
Market Ratios	141
Profitability Ratios	141
Research Methodology	142
Disclaimer	143
Contact Us	143

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Takeda Pharmaceutical Company Limited (4502:TYO) Strategic SWOT, PESTLE Analysis and Financial Insights - A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends

Company Report | 2025-02-27 | 142 pages | Quaintel Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$175.00
	Multi User Price	\$195.00
	Enterprise User Price	\$225.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-02

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com